Table 2.

Follow-Up of Recurrent Clostridioides difficile Infection Fecal Microbiota Transplantation Treatment Success of Patients Transferred With Blastocystis sp.–Positive Versus –Negative Donor Feces

Patients Outcome	Blastocystis sp.–Positive Donor Feces	Blastocystis sp.–Negative Donor Feces	Significance, OR [95% CI], P value
FMT success rate	83.9% (26/31)	92.7% (76/82)	0.411 [.12, 1.46], P value = .159
Relapses of CDI	16.1% (5/31)	7.3% (6/82)	2.436 [.69, 8.65], P value = .159
New CDI episode, >2 months after FMT	9.7% (3/31)	7.3% (6/82)	1.357 [.32, 5.80], P value = .704
CDI event: relapse or new episode	25.8% (8/31)	14.6% (12/82)	2.029 [.74, 5.88], P value = .165

Percentages and final ORs with 95% CIs of the FMT treatment outcome between patients treated with Blastocystis sp.–positive versus –negative donor feces. A χ2 test or Fischer exact test was performed in cases of n < 5.

Abbreviations: CDI, Clostridioides difficile infection; CI, confidence interval; FMT, fecal microbiota transplantation; OR, odds ratio.